ArticleThe Journal of antimicrobial chemotherapy2026
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens.
Article in The Journal of antimicrobial chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCountries faced with an impending shortage of antiretrovirals need to conserve supplies and maximize treatment effectiveness while limiting harms. Potential strategies to achieve this could include reduced doses of fixed-dose tenofovir disoproxil-lamivudine-dolutegravir (TLD).
methodsNonlinear mixed effects was applied to dolutegravir concentration-time data from three healthy volunteer studies (two including dolutegravir 'washout' over 10 and 15 days post-cessation), adapting a previously published model. The model was used to simulate (n = 1000) pharmacokinetic profiles of standard dolutegravir (one pill TLD daily) and four dose reduction strategies: half a pill TLD daily; one pill TLD every other day; 4 days on, 3 days off (4:3) and 5 days on, 2 days off (5:2) therapy. Proportions above and time below the EC90 (320 ng/mL) were determined and compared.
resultsSeventy-three volunteers (60% female, n = 825 concentrations) were included in the model. Marked differences between simulated dose reduction regimens were observed, with alternate day, 4:3 and 5:2 dosing, associated with a lower proportion of dolutegravir trough above the EC90 (41.6%-62.1%, 2.0%-5.2%, 14.1%-20.7%, respectively) across 50, 70 and 90 kg compared with daily dosing at full or half doses (88.7%-99.8%). Of the four dose reduction strategies, 4:3 dosing exhibited the longest predicted time below target before the next due dose (median ∼2 days).
conclusionsSafety and effectiveness of TLD dose reduction strategies can only be established in clinical studies and cannot be extrapolated from models. However, these models can inform regimen design to limit the window of opportunity for emergence of resistance, i.e. where viral replication occurs in the presence of appreciable drug concentrations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.